Publications

We invite you to explore Bayer-supported publications. This library is not intended to serve as a comprehensive repository of all publications. Publications not supported by Bayer are not included. Access to the full text of publications may depend on journal access rights.

To help narrow down your search, choose the relevant tags and click Apply. Selecting multiple tags will narrow your results.

Last updated July 6, 2026.

Colorectal Cancer

Hepatocellular Cancer

Other Solid Tumors

Prostate Cancer

Thyroid Cancer

Types of Enhancements Available

Audio

Infographic

Plain Language Summary

Video

Other

Efficacy and safety of darolutamide plus androgen-deprivation therapy in Black patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trial

Trinh Q.-D. et al. Prostate Cancer and Prostatic Diseases. 2026: 1-4.

Trinh QD, George DJ, Shore N, Vjaters E, Olmos D, de Santana Gom,

READ

Radiological progression-free survival as a surrogate for overall survival in patients with metastatic hormone-sensitive prostate cancer: A bivariate meta-analysis

Shore N., et al. European Journal of Cancer. 2025;223:115513.

Shore N.; Morgans A.K.; Boegemann M.; Gallagher E.; Paracha N.; ,

READ

Drug Utilisation of Radium-223 Under Routine Clinical Practice (DIRECT) in Europe: A Post-Authorisation Safety Study

Weinrib R., et al. Oncology and Therapy. 2025.

Weinrib R.; Fortuny J.; Martinez D.; Kollhorst B.; Haug U.; ,

READ

COREGO: drug–drug interaction analysis on the efficacy and safety of regorafenib in patients with a sarcoma: pooled analysis of the data from the REGOSARC and REGOBONE trials

Rethouse F., et al. ESMO Open. 2025;10(6):105117.

Rethouze F.; Risbourg S.; Schiffler C.; Chabaud S.; de Courrèges,

READ

Expert Opinion on Current Treatment Alternatives for Patients With Prostate Cancer Progressing From the Metastatic Hormone-Sensitive Stage to the Castration-Resistant Stage After Receiving Early Treatment Intensification

Vázquez-Estévez S., et al. Clinical Genitourinary Cancer. 2025;23(3):102338

Vázquez-Estévez S.; Gallardo E.; Fernández-Calvo O.; Juan-Fita M,

READ

Imatinib alternating with regorafenib compared to imatinib alone for the first-line treatment of advanced gastrointestinal stromal tumor: The AGITG ALT-GIST intergroup randomized phase II trial: Clinical Studies

Yip D., et al. British Journal of Cancer. 2025;132(10):897-904.

Yip D.; Zalcberg J.; Blay J.-Y.; Eriksson M.; Espinoza D.; Price,

READ

Retreatment of Metastatic Castration-Resistant Prostate Cancer Patients with 223Ra Therapy in Daily Practice

van Riel J.H.H.M.; Donswijk M.L.; Brouwer C.; Gerritsen W.R.; Ta,

READ

Regorafenib as maintenance therapy after first-line doxorubicin-based chemotherapy in advanced non-adipocytic soft tissue sarcomas patients: a double-blind randomised trial

Penel N., et al. Annals of Oncology. 2025;36(8):944 - 953.

Penel N.; Italiano A.; Wallet J.; Chaigneau L.; Verret B.; ,

READ

Association of Deep and Durable Prostate-specific Antigen Responses with Outcomes in Metastatic Hormone-sensitive Prostate Cancer: Insights from ARASENS and ARANOTE Trials

Wallis C.J.D., et al. European Urology Oncology. 2025.

Wallis C.J.D.; Ekberg S.; Morgans A.K.; Boegemann M.; Parach,

READ

Cost-effectiveness analysis of regorafenib dose optimization for refractory metastatic colorectal cancer

Weinrib R., et al. Oncology and Therapy. 2025.

Bekaii-Saab T.; Cho S.K.; Hocum B.; Grossman J.; Appukkuttan,

READ

You are encouraged to report side effects or quality complaints of products to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088. For Bayer products, you can report these directly to Bayer by clicking here.

This site provides access to balanced and evidence-based medical information related to our therapeutic areas of focus and is intended to serve as a medical resource for US HCPs. This may include investigational compounds or investigational new uses of FDA-approved Bayer products. The information provided is not intended to be promotional or provide medical advice. Please refer to the full Prescribing Information for approved indications, contraindications, warnings and precautions, and adverse events.

Site last updated 02/2026

Welcome to Bayer US Medical Affairs

Publications

Publications

Types of Enhancements Available

Efficacy and safety of darolutamide plus androgen-deprivation therapy in Black patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trial

Radiological progression-free survival as a surrogate for overall survival in patients with metastatic hormone-sensitive prostate cancer: A bivariate meta-analysis

Drug Utilisation of Radium-223 Under Routine Clinical Practice (DIRECT) in Europe: A Post-Authorisation Safety Study

COREGO: drug–drug interaction analysis on the efficacy and safety of regorafenib in patients with a sarcoma: pooled analysis of the data from the REGOSARC and REGOBONE trials

Expert Opinion on Current Treatment Alternatives for Patients With Prostate Cancer Progressing From the Metastatic Hormone-Sensitive Stage to the Castration-Resistant Stage After Receiving Early Treatment Intensification

Imatinib alternating with regorafenib compared to imatinib alone for the first-line treatment of advanced gastrointestinal stromal tumor: The AGITG ALT-GIST intergroup randomized phase II trial: Clinical Studies

Retreatment of Metastatic Castration-Resistant Prostate Cancer Patients with 223Ra Therapy in Daily Practice

Regorafenib as maintenance therapy after first-line doxorubicin-based chemotherapy in advanced non-adipocytic soft tissue sarcomas patients: a double-blind randomised trial

Association of Deep and Durable Prostate-specific Antigen Responses with Outcomes in Metastatic Hormone-sensitive Prostate Cancer: Insights from ARASENS and ARANOTE Trials

Cost-effectiveness analysis of regorafenib dose optimization for refractory metastatic colorectal cancer